In the past week, MIRM stock has gone up by 4.83%, with a monthly gain of 13.17% and a quarterly surge of 7.79%. The volatility ratio for the week is 0.63%, and the volatility levels for the last 30 days are 1.72% for Mirum Pharmaceuticals Inc The simple moving average for the last 20 days is 9.20% for MIRM stock, with a simple moving average of 16.15% for the last 200 days.
Is It Worth Investing in Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Right Now?
Moreover, the 36-month beta value for MIRM is 0.95. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MIRM is 40.03M and currently, short sellers hold a 15.14% of that float. On June 19, 2025, MIRM’s average trading volume was 432.91K shares.
MIRM) stock’s latest price update
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) has seen a rise in its stock price by 0.20 in relation to its previous close of 50.70. However, the company has experienced a 4.83% gain in its stock price over the last five trading sessions. investors.com reported 2025-06-17 that Biotech stock Mirum Pharmaceuticals has rocketed 236% since its IPO in 2019. Shares are near a buy point after earnings.
Analysts’ Opinion of MIRM
Many brokerage firms have already submitted their reports for MIRM stocks, with H.C. Wainwright repeating the rating for MIRM by listing it as a “Buy.” The predicted price for MIRM in the upcoming period, according to H.C. Wainwright is $73 based on the research report published on May 19, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see MIRM reach a price target of $48. The rating they have provided for MIRM stocks is “Buy” according to the report published on April 17th, 2024.
H.C. Wainwright gave a rating of “Buy” to MIRM, setting the target price at $58 in the report published on December 18th of the previous year.
MIRM Trading at 15.95% from the 50-Day Moving Average
After a stumble in the market that brought MIRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.33% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MIRM starting from Fairey William, who sale 3,203 shares at the price of $48.42 back on Jun 11 ’25. After this action, Fairey William now owns 2,500 shares of Mirum Pharmaceuticals Inc, valued at $155,091 using the latest closing price.
WILLIAM C FAIREY, the Director of Mirum Pharmaceuticals Inc, proposed sale 3,203 shares at $48.42 during a trade that took place back on Jun 11 ’25, which means that WILLIAM C FAIREY is holding shares at $155,091 based on the most recent closing price.
Stock Fundamentals for MIRM
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.77 for the gross margin
The net margin for Mirum Pharmaceuticals Inc stands at -0.2. The total capital return value is set at -0.14. Equity return is now at value -33.06, with -11.52 for asset returns.
Based on Mirum Pharmaceuticals Inc (MIRM), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at 1.36. The interest coverage ratio of the stock is -5.33.
Currently, EBITDA for the company is -48.97 million with net debt to EBITDA at -2.8. When we switch over and look at the enterprise to sales, we see a ratio of 6.91. The receivables turnover for the company is 3.96for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.22.
Conclusion
To wrap up, the performance of Mirum Pharmaceuticals Inc (MIRM) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
